Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glucose Control Clear all
Completed Not applicable Interventional Results available

The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System

NCT03674281
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Cognitive Change
Interventions
SAP, CLC
Device
Lead sponsor
University of Virginia
Other
Eligibility
6 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jul 24, 2026, 4:08 AM EDT
Withdrawn Not applicable Interventional

Embecta AID System in Adults With Type 2 Diabetes

NCT06692153
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 DM, T2DM With Inadequate Glycemic Control, T2DM (Type 2 Diabetes Mellitus), T2D, T2DM
Interventions
An AID System., Standard of Care (SC)
Device · Other
Lead sponsor
Embecta Corp.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Palo Alto, California • Walnut Creek, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

NCT01297062
View directory record Official record
Conditions
Healthy Subjects
Interventions
Exenatide, Moxifloxacin, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jul 24, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Effect of Fiber Supplementation on the Need for Medication With Gestational Diabetes

NCT06867861
View directory record Official record
Conditions
Gestational Diabetes Mellitus (GDM)
Interventions
Fiber
Dietary Supplement
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 3 Interventional

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

NCT00046462
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Metformin, Glyburide, Thiazolidinedione
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)

NCT00961662
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
D-Tagatose
Drug
Lead sponsor
Robert Lodder
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Garden Grove, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Jul 24, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Diabetes Screening Immediately Postpartum (DIP) and Follow Up PP CARE

NCT05909046
View directory record Official record
Conditions
Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk, Gestational Diabetes, Gestational Diabetes Mellitus in the Puerperium
Interventions
Immediate inpatient postpartum OGTT, Standard of care 4-12 week postpartum OGTT
Diagnostic Test
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

NCT02010242
View directory record Official record
Conditions
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Interventions
GKT137831, Placebo
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Tucson, Arizona • Orange, California • Coral Gables, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

NCT02202161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Sitagliptin, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

NCT01240759
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 24, 2026, 4:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glycemic Control, Brain Structure and Cognition in Youth With Type 1 Diabetes (T1DM)

NCT00879203
View directory record Official record
Conditions
Type 1 Diabetes Mellitis, Cognition
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
7 Years to 16 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

NCT01774968
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Regular U-500 Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Jul 24, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Fresh Takes!: An Evaluation of the Impact of Receiving Fresh Food Boxes

NCT06019624
View directory record Official record
Conditions
Diabetes, PreDiabetes, Food Insecurity
Interventions
Fresh Takes!
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jul 24, 2026, 4:08 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Sugary Drink Warning Labels

NCT03654586
View directory record Official record
Conditions
Obesity, Diabetes, Weight Gain
Interventions
Sugary drink warning labels
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jul 24, 2026, 4:08 AM EDT
Active, not recruiting Phase 2 Interventional

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

NCT05743244
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 35 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers

NCT00606112
View directory record Official record
Conditions
Diabetes Mellitus, Obesity
Interventions
Trodusquemine (MSI-1436)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2009 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Electronic Decision Support for Intervention in Poorly Controlled Type 2 Diabetes

NCT02924207
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
PATH electronic decision support tool
Other
Lead sponsor
St Elizabeth Healthcare
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Covington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Cryovagotomy Diabetes Trial

NCT04276051
View directory record Official record
Conditions
Diabetes Type 2, Diabetes Mellitus, Obesity
Interventions
Cryoablation of the Vagus Nerve, Lifestyle Intervention
Device · Behavioral
Lead sponsor
Emory University
Other
Eligibility
22 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery

NCT03770637
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia
Interventions
Glucagon RTU, Placebo
Drug · Other
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 24, 2026, 4:08 AM EDT
Terminated Phase 1 Interventional

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

NCT00637338
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-04603629, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

NCT01498185
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Chula Vista, California • San Diego, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

NCT00491543
View directory record Official record
Conditions
Diabetes, Coronary Artery Disease
Interventions
ALT-2074
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2008 · Synced Jul 24, 2026, 4:08 AM EDT
Withdrawn Phase 4 Interventional

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

NCT01971047
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Regular Insulin, Humalog
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Jul 24, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pistachios Blood Sugar Control, Heart and Gut Health

NCT04056208
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Diseases
Interventions
Pistachio, Usual care
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 24, 2026, 4:08 AM EDT